{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T18:24:23Z","timestamp":1789928663213,"version":"4.0.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.phrs.2017.03.011","type":"journal-article","created":{"date-parts":[[2017,3,19]],"date-time":"2017-03-19T10:30:29Z","timestamp":1489919429000},"page":"138-145","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Influence of MDR1 and CYP3A5 genetic polymorphisms on trough levels and therapeutic response of imatinib in newly diagnosed patients with chronic myeloid leukemia"],"prefix":"10.1016","volume":"120","author":[{"given":"Natarajan","family":"Harivenkatesh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalit","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Bakhshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atul","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhulika","family":"Kabra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thirumurthy","family":"Velpandian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Gogia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivaram S.","family":"Shastri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nihar Ranjan","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogendra Kumar","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"87","key":"10.1016\/j.phrs.2017.03.011_bib0005","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/ajh.23282","article-title":"Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management","volume":"2012","author":"Jabbour","year":"2012","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.phrs.2017.03.011_bib0010","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1053\/j.seminhematol.2010.06.003","article-title":"Current status of imatinib as frontline therapy for chronic myeloid leukemia","volume":"47","author":"Marin","year":"2010","journal-title":"Semin. Hematol."},{"issue":"122","key":"10.1016\/j.phrs.2017.03.011_bib0015","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia","volume":"2013","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2017.03.011_bib0020","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","article-title":"Clinical pharmacokinetics of imatinib","volume":"44","author":"Peng","year":"2005","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.phrs.2017.03.011_bib0025","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1158\/1078-0432.CCR-10-2250","article-title":"Drug transporters and imatinib treatment: implications for clinical practice","volume":"17","author":"Eechoute","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2017.03.011_bib0030","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrd839","article-title":"Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug","volume":"1","author":"Capdeville","year":"2002","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2017.03.011_bib0035","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/sj.clpt.6100201","article-title":"Imatinib disposition and ABCB1 (MDR1, P-glycoprotein) genotype","volume":"82","author":"Gurney","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2017.03.011_bib0040","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/gm206","article-title":"The pharmacogenetics of imanitib","volume":"2","author":"Dulucq","year":"2010","journal-title":"Genome Med."},{"key":"10.1016\/j.phrs.2017.03.011_bib0045","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1053\/j.seminhematol.2010.06.005","article-title":"Resistance to imatinib: mutations and beyond","volume":"47","author":"La Ros\u00e9e","year":"2010","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.phrs.2017.03.011_bib0050","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00228-009-0772-y","article-title":"CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity","volume":"66","author":"Gr\u00e9en","year":"2010","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"27","key":"10.1016\/j.phrs.2017.03.011_bib0055","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/fcp.12007","article-title":"Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experiencefrom 1216 patients at a centralized laboratory","author":"Bouchet","year":"2013","journal-title":"Fundam. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2017.03.011_bib0060","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1080\/17425255.2016.1184649","article-title":"Pharmacogenetics of tyrosine kinase inhibitors in gastrointestinal stromal tumor and chronic myeloid leukemia","volume":"12","author":"Ravegnini","year":"2016","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.phrs.2017.03.011_bib0065","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Chronic Myelogenous Leukemia; Version 1.2016."},{"key":"10.1016\/j.phrs.2017.03.011_bib0070","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/nar\/16.3.1215","article-title":"A simple salting out procedure for extracting DNA from human nucleated cells","volume":"16","author":"Miller","year":"1988","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.phrs.2017.03.011_bib0075","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1067\/mcp.2001.114164","article-title":"Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects","volume":"69","author":"Cascorbi","year":"2001","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2017.03.011_bib0080","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1093\/clinchem\/48.10.1668","article-title":"CYP3A5 variant allele frequencies in Dutch Caucasians","volume":"48","author":"van Schaik","year":"2002","journal-title":"Clin. Chem."},{"key":"10.1016\/j.phrs.2017.03.011_bib0085","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1007\/s00228-009-0621-z","article-title":"Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders","volume":"65","author":"Singh","year":"2009","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2017.03.011_bib0090","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S1570-0232(01)00611-0","article-title":"High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry","volume":"768","author":"Bakhtiar","year":"2002","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.phrs.2017.03.011_bib0095","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood-2010-12-326405","article-title":"BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet","volume":"118","author":"Soverini","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2017.03.011_bib0100","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/sj.leu.2403426","article-title":"Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance","volume":"18","author":"Hochhaus","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.phrs.2017.03.011_bib0105","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/sj.leu.2403257","article-title":"P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate","volume":"18","author":"Illmer","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.phrs.2017.03.011_bib0110","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(03)00979-3","article-title":"Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias","volume":"4","author":"Gambacorti-Passerini","year":"2003","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.phrs.2017.03.011_bib0115","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1182\/blood-2002-05-1366","article-title":"High levels of BAX, low levels of MRP-1, and high platelets are independent predictors of response to imatinib in myeloid blast crisis of CML","volume":"101","author":"Lange","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2017.03.011_bib0120","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/86882","article-title":"Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression","volume":"27","author":"Kuehl","year":"2001","journal-title":"Nat. Genet."},{"key":"10.1016\/j.phrs.2017.03.011_bib0125","doi-asserted-by":"crossref","first-page":"4750","DOI":"10.1158\/1078-0432.CCR-09-0145","article-title":"Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia","volume":"15","author":"Kim","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2017.03.011_bib0130","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/jhg.2010.98","article-title":"Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia","volume":"55","author":"Takahashi","year":"2010","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.phrs.2017.03.011_bib0135","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1093\/annonc\/mds532","article-title":"Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients","volume":"24","author":"Seong","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.phrs.2017.03.011_bib0140","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/1078155209104380","article-title":"Clinical significance of ABCB1 genotyping in oncology","volume":"16","author":"Hamidovic","year":"2010","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.phrs.2017.03.011_bib0145","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/S0169-409X(02)00064-9","article-title":"The influence of MDR1 polymorphisms on P-glycoprotein expression and function in humans","volume":"54","author":"Fromm","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.phrs.2017.03.011_bib0150","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.2174\/1568026043387692","article-title":"Pharmacogenetics of drug transporters and its impact on the pharmacotherapy","volume":"4","author":"Sakaeda","year":"2004","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.phrs.2017.03.011_bib0155","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1517\/phgs.4.4.397.22747","article-title":"Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs","volume":"4","author":"Sakaeda","year":"2003","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.phrs.2017.03.011_bib0160","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/sj.tpj.6500001","article-title":"Polymorphisms in the ABC drug transporter gene MDR1","volume":"1","author":"Brinkmann","year":"2001","journal-title":"Pharmacogenomics J."},{"key":"10.1016\/j.phrs.2017.03.011_bib0165","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/01.fpc.0000178311.02878.83","article-title":"Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C > t affects mRNA stability","volume":"15","author":"Wang","year":"2005","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.phrs.2017.03.011_bib0170","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/FPC.0b013e3283385a1c","article-title":"Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein)","volume":"21","author":"Hodges","year":"2011","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.phrs.2017.03.011_bib0175","first-page":"244","article-title":"Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia","volume":"33","author":"Yamakawa","year":"2011","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.phrs.2017.03.011_bib0180","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1182\/blood-2008-03-147744","article-title":"Multidrug resistance gene (MDR1) polymorphisms are associated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia","volume":"112","author":"Dulucq","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2017.03.011_bib0185","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.leukres.2010.12.004","article-title":"Correlation between genetic polymorphisms of the hOCT1 and MDR1 genes and the response to imatinib in patients newly diagnosed with chronic-phase chronic myeloid leukemia","volume":"35","author":"Maffioli","year":"2011","journal-title":"Leuk. Res."},{"key":"10.1016\/j.phrs.2017.03.011_bib0190","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1179\/1607845413Y.0000000102","article-title":"Association of MDR1 gene polymorphism (G2677T) with imatinib response in Egyptian chronic myeloid leukemia patients","volume":"19","author":"Elghannam","year":"2014","journal-title":"Hematology"},{"key":"10.1016\/j.phrs.2017.03.011_bib0195","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s12032-010-9456-9","article-title":"Multidrug resistance gene (MDR1) polymorphisms correlate with imatinib response in chronic myeloid leukemia","volume":"28","author":"Ni","year":"2010","journal-title":"Med. Oncol."},{"key":"10.1016\/j.phrs.2017.03.011_bib0200","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.3892\/ol.2014.1857","article-title":"ABCB1 haplotypes are associated with P-gp activity and affect a major molecular response in chronic myeloid leukemia patients treated with a standard dose of imatinib","volume":"7","author":"Vivona","year":"2014","journal-title":"Oncol. Lett."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104366181630740X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104366181630740X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,4]],"date-time":"2020-10-04T03:32:04Z","timestamp":1601782324000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104366181630740X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":40,"alternative-id":["S104366181630740X"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2017.03.011","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Influence of MDR1 and CYP3A5 genetic polymorphisms on trough levels and therapeutic response of imatinib in newly diagnosed patients with chronic myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2017.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}